Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus platinum-doublet neoadjuvant chemotherapy for resectable stage IB-IIIA non-small cell lung cancer
ChiCTR2100053389Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoints: Major pathological remission and Event-free survival. Started Dec 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100053389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053389.